AR123855A1 - PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE - Google Patents

PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Info

Publication number
AR123855A1
AR123855A1 ARP210102890A ARP210102890A AR123855A1 AR 123855 A1 AR123855 A1 AR 123855A1 AR P210102890 A ARP210102890 A AR P210102890A AR P210102890 A ARP210102890 A AR P210102890A AR 123855 A1 AR123855 A1 AR 123855A1
Authority
AR
Argentina
Prior art keywords
cdr
seq
amino acid
acid sequence
peg
Prior art date
Application number
ARP210102890A
Other languages
Spanish (es)
Inventor
Wei Liang
- Lin Weiyu Ching
Yan Wu
Minhong Yan
Breanna Sachiko Vollmar
Mingjian Fei
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR123855A1 publication Critical patent/AR123855A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Reivindicación 1: Un anticuerpo PEGilado que se une a MerTK, en donde el anticuerpo está conjugado con uno o más polímeros de polietilenglicol (PEG); en donde cada uno de los polímeros de PEG está conjugado con una cadena pesada o cadena liviana del anticuerpo en un residuo de cisteína modificada por ingeniería genética; y en donde el anticuerpo comprende: (1) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de SYAMG (SEQ ID Nº 1), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IINSYGNTYYANWAKG (SEQ ID Nº 2), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de DPGVSSNL (SEQ ID Nº 3), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQNIYSGLA (SEQ ID Nº 4), (e) una CDR-L2 que comprende la secuencia de aminoácidos de GASKLAS (SEQ ID Nº 5), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QATYYSSNSVA (SEQ ID Nº 6); o (2) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de ANTMN (SEQ ID Nº 7), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IFTATGSTYYATWVNG (SEQ ID Nº 8), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de SGSGSSSGAFNI (SEQ ID Nº 9), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQSISSSLA (SEQ ID Nº 10), (e) una CDR-L2 que comprende la secuencia de aminoácidos de AASILAS (SEQ ID Nº 11), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QCTSYGSLFLGP (SEQ ID Nº 12).Claim 1: A PEGylated antibody that binds MerTK, wherein the antibody is conjugated to one or more polyethylene glycol (PEG) polymers; wherein each of the PEG polymers is conjugated to an antibody heavy chain or light chain at an engineered cysteine residue; and wherein the antibody comprises: (1) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the SYAMG amino acid sequence (SEQ ID NO: 1), (b) a CDR- H2 comprising the amino acid sequence of IINSYGNTYYANWAKG (SEQ ID NO 2), and (c) a CDR-H3 comprising the amino acid sequence of DPGVSSNL (SEQ ID NO 3), and a light chain (VL) variable domain. comprising (d) a CDR-L1 comprising the amino acid sequence of QASQNIYSGLA (SEQ ID NO: 4), (e) a CDR-L2 comprising the amino acid sequence of GASKLAS (SEQ ID NO: 5), and (f) a CDR-L3 comprising the amino acid sequence of QATYYSSNSVA (SEQ ID NO: 6); or (2) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the amino acid sequence of ANTMN (SEQ ID NO: 7), (b) a CDR-H2 comprising the sequence of amino acids of IFTATGSTYYATWVNG (SEQ ID NO: 8), and (c) a CDR-H3 comprising the amino acid sequence of SGSGSSSGAFNI (SEQ ID NO: 9), and a light chain (VL) variable domain comprising (d) a CDR-L1 comprising the amino acid sequence of QASQSISSSLA (SEQ ID No. 10), (e) a CDR-L2 comprising the amino acid sequence of AASILAS (SEQ ID No. 11), and (f) a CDR-L3 comprising the amino acid sequence of QCTSYGSLFLGP (SEQ ID NO: 12).

ARP210102890A 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE AR123855A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063094197P 2020-10-20 2020-10-20

Publications (1)

Publication Number Publication Date
AR123855A1 true AR123855A1 (en) 2023-01-18

Family

ID=78725615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102890A AR123855A1 (en) 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Country Status (3)

Country Link
AR (1) AR123855A1 (en)
TW (1) TW202233671A (en)
WO (1) WO2022086957A1 (en)

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US1624821A (en) 1926-03-26 1927-04-12 Sidney C Ashton Oil-well pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DK0979281T3 (en) 1997-05-02 2005-11-21 Genentech Inc Process for the preparation of multispecific antibodies with heteromultimers and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001007611A2 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA02003456A (en) 1999-10-04 2002-10-23 Medicago Inc Method for regulating transcription of foreign genes in the presence of nitrogen.
CN101289511A (en) 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
KR20100018071A (en) 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (en) 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2004003192A1 (en) 2002-06-28 2004-01-08 Bayer Healthcare Ag Human receptor tyrosine kinase mertk
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (en) 2002-12-16 2010-10-27 Genentech, Inc. VARIATIONS OF IMMUNOGLOBULIN AND ITS USES.
CA2513797C (en) 2003-01-22 2016-05-03 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN1961003B (en) 2004-03-31 2013-03-27 健泰科生物技术公司 Humanized anti-TGF-beta antibodies
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
JP4948413B2 (en) 2004-09-23 2012-06-06 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ES2755976T3 (en) 2005-02-07 2020-04-24 Roche Glycart Ag Antigen-binding molecules that bind to EGFR, vectors that encode them, and uses thereof
KR101498834B1 (en) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
DK2059533T3 (en) 2006-08-30 2013-02-25 Genentech Inc MULTI-SPECIFIC ANTIBODIES
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
ES2639857T3 (en) 2008-02-11 2017-10-30 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2225932B1 (en) 2009-03-03 2013-01-23 Institut de Recherche pour le Développement ( IRD) Method for enhancing market garden plant growth
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (en) 2009-04-07 2015-04-29 Roche Glycart Ag Trivalent, bispecific antibodies
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN101606769A (en) 2009-07-15 2009-12-23 陈德芳 A kind of gemstone connecting structure
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
KR101790767B1 (en) 2009-11-24 2017-10-26 메디뮨 리미티드 Targeted binding agents against b7-h1
RU2626537C2 (en) 2010-06-08 2017-07-28 Дженентек, Инк. Antibodies with cysteine substituitions and their conjugates produced by gene engineering
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
AU2012234335B2 (en) 2011-03-29 2016-09-01 Roche Glycart Ag Antibody Fc variants
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
CN103732238A (en) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 Therapeutic compounds for immunomodulation
SG2014008577A (en) 2011-08-23 2014-04-28 Roche Glycart Ag Bispecific antigen binding molecules
CN202382282U (en) 2011-09-30 2012-08-15 张伟生 Energy-saving gas stove
US20150018241A1 (en) 2012-02-15 2015-01-15 Hoffmann-La Roche Inc. Fc-receptor based affinity chromatography
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CN104736168B (en) 2012-05-31 2018-09-21 索伦托治疗有限公司 The antigen-binding proteins combined with PD-L1
CN105143262A (en) 2013-04-29 2015-12-09 豪夫迈·罗氏有限公司 Human fcrn-binding modified antibodies and methods of use
RS61400B1 (en) 2013-05-02 2021-02-26 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
CN103650585B (en) 2013-07-08 2017-11-21 华为技术有限公司 A kind of method and apparatus of cell switching
HUE039014T2 (en) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
TR201809838T4 (en) 2013-09-06 2018-07-23 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators.
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
HUE060420T2 (en) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
RU2020129339A (en) 2013-12-20 2020-10-02 Дженентек, Инк. ANTIBODIES WITH DUAL SPECIFICITY
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
ES2783026T3 (en) 2014-02-04 2020-09-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for the treatment of cancer
DK3102605T3 (en) 2014-02-04 2019-02-25 Pfizer COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATMENT OF CANCER
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
AU2015283802A1 (en) 2014-06-30 2017-02-16 Acn 616 222 309 Pty Ltd System and method for rendering buildings in three dimensions
JP6744292B2 (en) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
US10949507B2 (en) 2014-10-17 2021-03-16 Vulpecula, Llc. Methods, systems, and computer program products for web browsing
SG11201703925VA (en) 2014-12-02 2017-06-29 Celgene Corp Combination therapies
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
CN114364703A (en) * 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 Anti-merk antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2022086957A1 (en) 2022-04-28
TW202233671A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
ES2523740T3 (en) Monoclonal antibodies to the fibroblast growth factor 2 receptor
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
PE20221869A1 (en) BISECIFIC ANTIGEN-BINDING MOLECULES DIRECTED TO OX40 AND PAF
AR110659A1 (en) ANTI-NEUROPILIN ANTIGENS PROTEINS AND METHOD FOR USE
AR088579A1 (en) FORMULATIONS OF ANTIBODIES
PE20080980A1 (en) ANTI-LYMPHOTOXIN ALPHA ANTIBODIES
PE20141186A1 (en) TNF-ALPHA BINDING PROTEINS
PE20120211A1 (en) ANTIBODIES THAT HAVE HUMAN OX40 SPECIFICITY
PE20211709A1 (en) ANTIBODIES THAT RECOGNIZE TAU
RS54197B1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AR080243A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
PE20140848A1 (en) MONOCLONAL ANTIBODIES AGAINST RGMA PROTEIN AND ITS USES
PE20220279A1 (en) SPECIFIC INHIBITORS OF THE LTBP COMPLEX OF TGF BETA AND USES THEREOF
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
RU2019124709A (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN
PE20121645A1 (en) COMPOSITIONS AND METHODS TO TREAT INFLAMMATORY DISORDERS
CO6180454A2 (en) ANTIBODIES OF EGFL7 AND METHODS OF USE
PE20230844A1 (en) ANTI-NECTIN-4 ANTIBODY, CONJUGATE WHICH INCLUDES IT AND APPLICATION THEREOF
RU2018106456A (en) ANTIBODY TO EPHA4
PE20231504A1 (en) SPECIFIC ANTIBODIES FOR KRAS AND THEIR USES
PE20230408A1 (en) ANTI-LILRB1 ANTIBODY AND USES THEREOF
AR115192A1 (en) ANTIBODIES
RU2021128024A (en) METHODS FOR CULTIVATION OF CELLS
AR123855A1 (en) PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure